The European Commission approved Imbruvica (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukemia, expanding upon the initial approval in October 2014 for certain patients with CLL. This decision comes one month after the Committee for Medicinal Products for Human Use issued an opinion in favor of the use of Imbruvica...
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
